Abstract | OBJECTIVE: METHODS: Continuous intravenous infusion of CGS 26303 at doses of 2.4, 8.0, or 24.0 mg/kg/d was initiated either 1 hour (prevention paradigm) or 24 hours (reversal paradigm) after experimental SAH in New Zealand White rabbits. All animals were killed by perfusion-fixation 48 hours after SAH. Basilar arteries were then removed and sectioned, and their cross-sectional areas were measured by use of computer-assisted video microscopy. RESULTS: Continuous intravenous infusion of CGS 26303 attenuated SAH-induced cerebral vasospasm in a dose-dependent manner in both the prevention and the reversal groups. These effects achieved statistical significance at all doses as compared with the SAH-only or SAH-plus-vehicle groups. Furthermore, the attenuation of vasospasm after continuous infusion of CGS 26303 was more efficacious than that obtained with bolus injections. CONCLUSION:
|
Authors | A L Kwan, C L Lin, C Z Chang, H J Wu, S L Hwong, A Y Jeng, K S Lee |
Journal | Neurosurgery
(Neurosurgery)
Vol. 49
Issue 2
Pg. 422-7; discussion 427-9
(Aug 2001)
ISSN: 0148-396X [Print] United States |
PMID | 11504119
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Organophosphonates
- Protease Inhibitors
- Tetrazoles
- CGS 26303
- Aspartic Acid Endopeptidases
- Metalloendopeptidases
- Endothelin-Converting Enzymes
|
Topics |
- Animals
- Aspartic Acid Endopeptidases
(antagonists & inhibitors)
- Endothelin-Converting Enzymes
- Infusions, Intravenous
- Male
- Metalloendopeptidases
- Organophosphonates
(therapeutic use)
- Protease Inhibitors
(therapeutic use)
- Rabbits
- Subarachnoid Hemorrhage
(complications)
- Tetrazoles
(therapeutic use)
- Vasospasm, Intracranial
(drug therapy, etiology, prevention & control)
|